{"nctId":"NCT00448669","briefTitle":"Botswana TDF/FTC Oral HIV Prophylaxis Trial","startDateStruct":{"date":"2007-03"},"conditions":["HIV Infections"],"count":1219,"armGroups":[{"label":"TDF-FTC,condoms,adh/risk counseling","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg"]},{"label":"Placebo,condoms,adh/risk counseling","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo Oral Tablet"]}],"interventions":[{"name":"Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg","otherNames":["Truvada"]},{"name":"Placebo Oral Tablet","otherNames":["Placebo"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* citizen of Botswana 18-39 years old\n* sexually active\n* HIV uninfected\n* Hepatitis B and C uninfected\n* Calculated creatinine clearance \\>= 60 mL/min\n* hemoglobin \\>= 8 gm/dL\n* ALT and AST \\<= 2x ULN\n* total bilirubin \\<= 1.5 mg/dL\n* total serum amylase \\<= 1.5x ULN\n* Serum phosphorus \\>= 2.2 mg/dL\n* willing to use hormonal contraception (females)\n* living within 1 hours travel of study clinic\n* pass comprehension test\n* willing and able to give informed consent\n\nExclusion Criteria:\n\n* 18-20 without parent/guardian consent\n* history of significant renal or bone disease\n* any chronic illness requiring ongoing prescription medication\n* pregnant or breastfeeding\n* planning to move away from site in the next year\n* participating in another HIV prevention or vaccine safety trial\n* any other clinical condition or prior therapy that, in the opinion of the study physician, would make the volunteer unsuitable for the study or unable to comply with the dosing requirements","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"39 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Adverse Drug Reactions in the Tenofovir/Emtricitabine and Placebo Arms","description":"Study visits were scheduled every 30 days until completion of the study, and participants were instructed to return to the clinic for evaluation in the event of an illness. Participants reported any adverse effects at monthly visits and interim visits.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91.2","spread":null},{"groupId":"OG001","value":"88.2","spread":null}]}]}]},{"type":"PRIMARY","title":"HIV Incidence in the Tenofovir/Emtricitabine and Placebo Arms","description":"Study visits were scheduled every 30 days until completion of the study and during monthly study visits, we performed testing for HIV infection. At completion of the study, we tested all participants for HIV infection, using an enzyme-linked immunosorbent assay (ELISA).The primary efficacy end point was the difference in the rates of HIV infection between participants assigned to receive TDF-FTC and those assigned to receive placebo. The initial efficacy analysis included all study participants who were randomly assigned to receive a study medication (intention-to-treat cohort).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":null},{"groupId":"OG001","value":"3.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Changes in Condom Use During Study: Number of Participants With >=1 Condomless Sex Acts","description":"We assessed condom use of the enrolled participants by face-to-face interviews (at baseline and monthly thereafter) and provided a comprehensive package of HIV prevention services, including individualized counseling on risk reduction, free male and female condoms, and screening for sexually transmitted infections followed, if applicable, by partner notification and treatment.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"124","spread":null},{"groupId":"OG001","value":"113","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94","spread":null},{"groupId":"OG001","value":"86","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97","spread":null},{"groupId":"OG001","value":"90","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92","spread":null},{"groupId":"OG001","value":"83","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73","spread":null},{"groupId":"OG001","value":"66","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null},{"groupId":"OG001","value":"61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70","spread":null},{"groupId":"OG001","value":"67","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55","spread":null},{"groupId":"OG001","value":"45","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57","spread":null},{"groupId":"OG001","value":"49","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55","spread":null},{"groupId":"OG001","value":"45","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null},{"groupId":"OG001","value":"36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]}]},{"type":"SECONDARY","title":"Rates of Adherence to Study Medication","description":"The rates of adherence to study medication by treatment arm was assessed over the entire course of the study. This comparison was done by assessing the percentage of pills taken by participants within each study arm. The difference between the 2 arms was compared with a Fisher' exact test.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93.5","spread":"0.136"},{"groupId":"OG001","value":"93.6","spread":"0.137"}]}]}]},{"type":"SECONDARY","title":"Antiretroviral (ARV) Resistance Patterns in Seroconverters","description":"Participants who seroconverted had blood samples taken at the time of infection and at one month and six months post seroconversion to detect any HIV resistance mutations.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"CD4 Evaluation After HIV Seroconversion","description":"Study medication was stopped when HIV infected was diagnosed. Seroconvertors were referred for clinical care and followed an additional year with scheduled quarterly CD4+ cell count assessments. A model-estimated geometric mean of the CD4+ cell counts by each treatment group was evaluated.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"500","spread":null},{"groupId":"OG001","value":"466","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":42,"n":611},"commonTop":["Amylase, Serum","Upper Respiratory Infection","Headache","Pain, Abdominal","Phosphate"]}}}